Latest Interviews
Showing 1–2 of 2 transcripts.
Clear all filters- Y Combinator21 min
BillionToOne Is Solving One of Biotech’s Hardest Problems
Jared Friedman, David Tsao, Oguzhan Atay
Billion to One, founded by PhD students Oguzhan and David, leverages proprietary synthetic DNA methods to detect rare cell-free DNA variations for prenatal screening and cancer liquid biopsies. Since its public listing with a valuation over $4 billion, the company has scaled its automated facility to process 600,000 tests annually and launched North Star Select for late-stage cancer treatment guidance. The firm now executes a strategic roadmap to address early-stage cancers through a capital-efficient progression from commercial adoption to population-wide screening, aiming to significantly reduce cancer mortality rates.
- Y Combinator1 min
Does YC Fund Solo Founders? - Jared Friedman
Y Combinator actively funds solo founders, reserving at least 10% of its batches for single-leader ventures despite a general preference for co-founding teams. History supports this inclusion, as successful entities like Dropbox and Zenefits were solo-led upon application before later acquiring co-founders. Although the program advises that co-founders improve success odds, joining with a partner after acceptance remains optional rather than mandatory.